Serial Fasciculation Measurements in Motor Neurone Disease

Status Completed

Clinical Trial Summary

Patients with motor neurone disease (MND) typically experience relentless motor decline and die within three years of symptom onset from respiratory muscle weakness. There are currently no effective therapies and the discovery of novel therapies is hampered by the lack of a sensitive disease biomarker. Consequently, there is a huge drive to discover novel biomarkers, which can reliably track disease progression over time. These can then be incorporated into clinical drug trials to expedite effective drug discovery.

Muscle fasciculations represent the hyperexcitability of diseased motor neurons and are almost universally present from the early stages of MND. The investigators predict that the site, frequency and shape of fasciculations might provide a sensitive measure of disease progression in an individual.

In order to calibrate this technique, the investigators will conduct a 12-month longitudinal study, recruiting 24 patients from the King's College Hospital Motor Nerve Clinic, comprising a mixture of patients with MND and those with benign fasciculation syndrome. Patients in this latter group have fasciculations but do not develop weakness and have normal lifespans. They are therefore an optimal control group. At each visit, the investigators will take resting HDSEMG recordings from all four limbs and perform standard clinical measures of disease progression. The investigators will also monitor the decline in motor unit number using a newly validated neurophysiological technique, called Motor Unit Number Index (MUNIX).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03809845
Study type	Interventional
Source	King's College Hospital NHS Trust
Contact
Status	Completed
Phase	N/A
Start date	July 6, 2017
Completion date	March 1, 2019

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04579666` - MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)	Phase 2
Completed	`NCT03706391` - Study of ALS Reversals 4: LifeTime Exposures
Active, not recruiting	`NCT03067857` - Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease	Phase 1/Phase 2
Completed	`NCT02464748` - Telehealth in Motor Neurone Disease	N/A
Completed	`NCT00956488` - Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis	Phase 1/Phase 2
Terminated	`NCT00537446` - Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis	N/A
Recruiting	`NCT04944940` - Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
Recruiting	`NCT03362658` - Novel MRI Biomarkers for Monitoring Disease Progression in ALS
Completed	`NCT00714636` - Cerebrospinal Fluid Repository	N/A
Completed	`NCT00076687` - Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function	Phase 2
Completed	`NCT00071435` - Brain Function in Primary Lateral Sclerosis	N/A
Completed	`NCT00001220` - Ultrasound and Videofluoroscopy for Diagnosing Swallowing Disorders	N/A
Completed	`NCT03487263` - Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease	Phase 1
Enrolling by invitation	`NCT05725759` - Rehabilitation in SOD1 ALS Treated With Tofersen
Active, not recruiting	`NCT03811301` - [BrainConnexion] - Neurodevice Phase I Trial	N/A
Completed	`NCT02469896` - A Trial of Tocilizumab in ALS Subjects	Phase 2
Completed	`NCT02011204` - Study of Electrical Impedance Myography (EIM) in ALS	N/A
Completed	`NCT01495390` - A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers	N/A
Completed	`NCT02870634` - Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND	Phase 1
Recruiting	`NCT06201650` - Neurofilament Light Chain in Amyotrophic Lateral Sclerosis